ZCZhongbao Chen

Zhongbao Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhongbao Chen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Jiangqiao Zhou

    Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan 430060, China

    2 shared publications
  • Tao Qiu

    Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, China; Department of Urology, Renmin Hospital of Wuhan University, Wuhan, China

    2 shared publications
  • Bo Yu

    Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China

    1 shared publication
  • Bo Yu

    Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan 430060, China

    1 shared publication
  • Dalin He

    Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan 430060, China

    1 shared publication
  • Jiayu Guo

    Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China

    1 shared publication

Latest Publications

  • Open Access

    Houttuynia cordata Polysaccharide Alleviates Hepatic Ischemia-Reperfusion Injury by Regulating Macrophage Polarization via Inhibiting the TLR4/NF-κB Signaling Pathway

    by Bo Yu, Dalin He, Zhan Chen, Yujie Zhou, Jiangqiao Zhou, Tianyu Wang, Qiangmin Qiu, Zhongbao Chen, Xiaoxiong Ma, Jiefu Zhu, et al.

    Background: Hepatic ischemia-reperfusion injury (HIRI) is a major complication in liver surgery with limited therapeutic options. Houttuynia cordata polysaccharide (HCP), a key bioactive component of the traditional anti-inflammatory herb, has demonstrated immunomodulatory potential, but its effect on HIRI remains unclear. Methods: A murine model of 70% hepatic ischemia for 60 min followed by reperfusion was established. Mice were administered low-dose (50 mg/kg) or high-dose (100 mg/kg) HCP or the positive control N-acetylcysteine (150 mg/kg). Liver injury was assessed by serum ALT/AST levels, histopathology, oxidative stress markers, and inflammatory cytokines. Macrophage polarization and the TLR4/NF-κB pathway were analyzed using flow cytometry, qPCR, and Western blot. The TLR4 inhibitor TAK-242 was used for reverse validation, and molecular docking was performed to predict HCP binding to the TLR4/MD-2 complex. Results: HCP significantly attenuated HIRI-induced liver injury, as shown by reduced ALT/AST, improved histopathological scores, decreased MDA, increased SOD, and lower TNF-α and IL-6 levels. Mechanistically, HCP promoted a shift from M1 to M2 macrophage polarization, with increased CD206+ cells and Arg-1/IL-10 expression and decreased CD86+ cells and iNOS/IL-1β expression. HCP also suppressed TLR4/MyD88/NF-κB pathway activation, inhibiting NF-κB p65 phosphorylation and nuclear translocation. These protective effects were largely reversed by TAK-242 in vivo and in vitro. Molecular docking indicated stable binding between HCP and TLR4/MD-2. Conclusions: HCP protects against HIRI by targeting TLR4 to inhibit NF-κB signaling, thereby reprogramming macrophage polarization toward the M2 phenotype and alleviating inflammation and oxidative stress. These findings highlight HCP as a promising natural agent for HIRI intervention.


  • Open Access

    Mechanism of action of the nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome and its regulation in liver injury

    by Yifan Lu, Tianyu Wang, Bo Yu, Kang Xia, Jiayu Guo, Yiting Liu, Xiaoxiong Ma, Long Zhang, Jilin Zou, Zhongbao Chen, et al.

    Nucleotide-binding oligomerization domain (NOD)-like receptor protein 3 (NLRP3) is a cytosolic pattern recognition receptor that recognizes multiple pathogen-associated molecular patterns and damage-associated molecular patterns. It is a cytoplasmic immune factor that responds to cellular stress signals, and it is usually activated after infection or inflammation, forming an NLRP3 inflammasome to protect the body. Aberrant NLRP3 inflammasome activation is reportedly associated with some inflammatory diseases and metabolic diseases. Recently, there have been mounting indications that NLRP3 inflammasomes play an important role in liver injuries caused by a variety of diseases, specifically hepatic ischemia/reperfusion injury, hepatitis, and liver failure. Herein, we summarize new research pertaining to NLRP3 inflammasomes in hepatic injury, hepatitis, and liver failure. The review addresses the potential mechanisms of action of the NLRP3 inflammasome, and its regulation in these liver diseases.